Detail akcie Galapagos online

Business Summary: Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is engaged in the discovery and development of small molecule medicines with novel modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The Company focuses on developing a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. It develops transformational medicines in areas of high unmet need by combining internal with external science with the goal to add years of life and improve quality of life of patients across the globe. Galapagos NV also discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. The Company acquired CellPoint and AboundBio in order to develop a cell therapy, which is a potential transformative treatment of different types of cancer.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Galapagos NV revenues increased 3% to EUR287M. Net loss before extraordinary items decreased 94% to EUR4M. Revenues reflect Europe segment increase from EUR3.6M to EUR239.7M. Lower net loss reflects Interest income increase from EUR18.1M to EUR79.3M (income), Fair Value Adjustments on Other Assets increase from EUR6.9M to EUR38.3M (income).